Researchers developed a highly sensitive, analytic, quantitative immunofluorescence assay that may enable more patients with lung cancer to benefit from an approved targeted therapy.The test measures HER2, a commonly used biomarker for breast cancer.
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
The Cellular Cancer Biology Imaging Research (CCBIR) Centers are developing and testing enabling imaging technologies at the cellular and organ scales driven by specific fundamental…
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study investigating CLAG-M salvage chemotherapy and lintuzumab-Ac225, a radio-labeled antibody against CD33,…
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Neoadjuvant chemotherapy’s effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by the OSUCCC – James shows most people continue to…
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
